AXGN
AxoGen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$48.28
+2.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 251.2M | 225.2M | 187.3M | 159.0M | 138.6M |
| Cost of Revenue | 63.9M | 57.9M | 45.4M | 37.1M | 29.8M |
| Gross Profit | 187.3M | 167.4M | 142.0M | 121.9M | 108.8M |
| Operating Expenses | |||||
| R&D Expense | 36.0M | 32.9M | 27.8M | 27.3M | 25.6M |
| SG&A Expense | 164.1M | 142.3M | 117.5M | 116.0M | 112.9M |
| General & Admin Expense | 51.7M | 44.6M | 39.0M | 38.4M | 40.9M |
| Selling & Marketing Expense | 112.4M | 97.7M | 78.5M | 77.6M | 72.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 200.1M | 175.2M | 145.3M | 143.3M | 138.5M |
| Cost and Expenses | 264.0M | 233.1M | 190.6M | 180.5M | 168.3M |
| Operating Income (EBIT) | (12.8M) | (7.8M) | (3.3M) | (21.5M) | (29.7M) |
| Non-Operating | |||||
| Interest Income | 1.0M | — | — | — | — |
| Interest Expense | 12.6M | 7.7M | 8.2M | 2.8M | 624.0K |
| Net Interest Income | (11.6M) | (7.7M) | (8.2M) | (2.8M) | (624.0K) |
| Other Non-Op Income/Expense | (20.7M) | (7.9M) | (6.7M) | (254.0K) | 759.0K |
| Non-Operating Income (excl Interest) | 8.7M | 152.0K | (1.5M) | (2.6M) | (1.4M) |
| EBT (Pre-Tax Income) | (33.5M) | (15.7M) | (10.0M) | (21.7M) | (28.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (33.5M) | (15.7M) | (10.0M) | (21.7M) | (28.9M) |
| Earnings from Cont. Ops | (33.5M) | (15.7M) | (10.0M) | (21.7M) | (28.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (33.5M) | (15.7M) | (10.0M) | (21.7M) | (28.9M) |
| Per Share | |||||
| Basic EPS | ($0.67) | ($0.34) | ($0.23) | ($0.51) | ($0.69) |
| Diluted EPS | ($0.68) | ($0.34) | ($0.23) | ($0.51) | ($0.69) |
| Revenue Per Share | $4.71 | $4.89 | $4.23 | $3.71 | $3.29 |
| Shares | |||||
| Basic Shares Outstanding | 53.3M | 46.1M | 44.3M | 42.9M | 42.1M |
| Diluted Shares Outstanding | 53.3M | 46.1M | 44.3M | 42.9M | 42.1M |
| Profitability Metrics | |||||
| EBITDA | (14.8M) | 192.0K | 6.1M | (13.3M) | (23.5M) |
| D&A | 6.8M | 8.2M | 7.8M | 5.6M | 4.9M |
| EBIT | (21.6M) | (8.0M) | (1.8M) | (18.9M) | (28.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026